The basics

What are EGFR mutations?

EGFR (Epidermal Growth Factor Receptor) mutations are among the most common molecular alterations in non-small cell lung cancer (NSCLC), especially in patients who are never-smokers or light smokers. These mutations cause the EGFR protein to signal continuously, driving cancer growth. The key difference: EGFR-mutant cancers respond dramatically to targeted EGFR inhibitor drugs like osimertinib (Tagrisso), gefitinib (Iressa), erlotinib (Tarceva), and afatinib (Gilotrif).

Most clinical trials for EGFR-mutant lung cancer fall into two categories: first-line trials (for patients who haven't yet received targeted therapy) and progression trials (for patients whose cancer has progressed on a prior EGFR inhibitor, often osimertinib).

EGFR Mutation Types

Not all EGFR mutations are the same. Trial eligibility often depends on your specific mutation:

Exon 19 Deletion
~45% of EGFR mutations
The most common EGFR mutation. Highly responsive to all EGFR inhibitors. Largest trial portfolio, especially for post-progression scenarios.
L858R Mutation
~40% of EGFR mutations
Point mutation in exon 21. Also highly responsive to EGFR inhibitors. Similar trial eligibility as exon 19 deletions.
Exon 20 Insertion
~5-10% of EGFR mutations
Less common but harder to treat. Resistant to standard EGFR inhibitors; requires specific drugs like mobocertinib (Exkivity) or amivantamab. Growing trial portfolio.
Other EGFR Mutations
~5% of EGFR mutations
Includes G719X, L861Q, and complex mutations. Rarer, but trials exist for these subtypes. Requires careful verification with your oncologist.

EGFR Trial Pathways by Treatment History

First-Line (Treatment-Naive)

If you haven't received targeted therapy: first-generation EGFR inhibitors (erlotinib, gefitinib) vs. osimertinib (third-generation) vs. EGFR inhibitor + chemotherapy combinations. Most trials favor osimertinib or combination strategies.

Post-First-Line Progression

If you progressed on erlotinib or gefitinib: escalation to osimertinib (if T790M resistance mutation present) or clinical trials testing osimertinib combinations.

Post-Osimertinib Progression

If you progressed on osimertinib: trials for acquired resistance mechanisms (MET amplification, C797S mutations, KRAS co-mutations). This is the fastest-growing trial segment.

Brain Metastases

EGFR inhibitors penetrate the blood-brain barrier well. Trials specifically designed for brain-involved EGFR-mutant disease are increasingly available.

Related Lung Cancer Biomarkers

If you're EGFR wild-type or have additional molecular alterations, you may also qualify for trials targeting these biomarkers:

KRAS G12C ALK Fusion ROS1 Fusion MET Exon 14 PD-L1 Expression RET Fusion
Common questions

EGFR Mutation FAQs

Both are common EGFR mutations (~85% of EGFR-mutant cases combined), and both respond similarly to EGFR inhibitors. The main difference is mechanistic: exon 19 deletions remove amino acids from the EGFR protein, while L858R is a point mutation that adds an amino acid. From a clinical trial perspective, they're usually treated identically — but always verify trial-specific eligibility, as rare trials may be mutation-specific.

After osimertinib progression, trial eligibility depends on your acquired resistance mechanism (identified via liquid biopsy or repeat biopsy): MET amplification trials (tepotinib, capmatinib combinations), EGFR C797S mutation trials, EGFR + MEK inhibitor combinations, and immunotherapy combinations for high PD-L1 patients. Getting molecular testing after progression is critical — it determines which trials you qualify for.

Often yes. Many EGFR trials allow stable, treated brain metastases. Some specifically design cohorts for brain-involved EGFR-mutant NSCLC. EGFR inhibitors cross the blood-brain barrier reasonably well, making brain metastases less of a trial barrier than with other drugs. Discuss with your neuro-oncologist which trials permit your specific brain involvement pattern.

Exon 20 insertions are inherently resistant to standard EGFR inhibitors. Trials focus on specialized drugs: mobocertinib (Exkivity) — an exon 20-specific inhibitor, amivantamab — a monoclonal antibody combination, and combination trials pairing these agents with chemotherapy or immunotherapy. Getting molecular confirmation of exon 20 insertion is critical, as trial eligibility is tightly restricted to this specific mutation.

(1) Pathology or NGS report confirming your exact EGFR mutation (exon 19, L858R, exon 20, etc.). (2) Recent imaging (CT, PET scan) showing current disease extent and location of metastases. (3) List of prior EGFR inhibitors with start/end dates and whether you progressed or had toxicity. (4) For post-progression trials: liquid or tissue biopsy results showing your acquired resistance mechanism. (5) Recent blood work and ECOG performance status from your oncologist.

Ready to find your matching EGFR trials?

Upload your pathology report, NGS results, or imaging. We'll identify your exact EGFR mutation, match you to recruiting trials, and give you an eligibility breakdown for each one.